Entering text into the input field will update the search result below

Hologic CEO Steve MacMillan says he's not leaving after taking on Illumina chair role

Aug. 01, 2023 11:10 AM ETHologic, Inc. (HOLX), ILMNBy: Joshua Fineman, SA News Editor4 Comments
Sign and logo of the Illumina company

Georgejason/iStock Editorial via Getty Images

Hologic Inc. (NASDAQ:HOLX) CEO Steve MacMillan said he doesn't plan to go anywhere after he was appointed chairman of Illumina (NASDAQ:ILMN) in June.

"Let’s be really clear, I’m going to be at Hologic through the end of my useful life in terms of

Recommended For You

Comments (4)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Problem is Illumina. They overplayed their hand during Covid & with Grail turning into a fiasco.

Illumina needs scientists, researchers & innovators to stand out. But the management has invested in marketeers & the useless middlemen/managers.

Returning to the fundamentals that got them here and getting rid of the wasteful layers of management would be the first thing a new leader should focus on.
bluescorpion0 profile picture
Souza 2.0? The problem is probably larger, namely this is not going to be a great moat business any longer. It is going to be like any other capital goods or inkjet cartridge type business. Did you see the number of companies launching sequencers? Dime a dozen. Like lasers industry, or semi industry this is at high risk of low valuation and intense competition. Yeah they make some software too which probably will keep the valuation elevated (something like ROK, for example). The other problem is that like defense/government spending which is generally bad business, this is even worse - academic business. And that gets even less funding than defense! I guess drug companies use this and is part of their r&d input, but then you are investing like a CROs, in the capex budget of drug discovery, perhaps like CRL.
I just saw MacMillan's interview on CNBC. Of course, he defended his decision to accept the ILMN role and contends the share price is suffering today due to some analyst's realization that most of the Covid test revenue won't return.
As a HOLX shareholder, I'm not pleased that MacMillan has a concurrent lead role in ILMN. Although Elon and a few others have shown that it's possible, I don't think it's good policy. Was ILMN so desperate for a replacement that they hired a part-time chair? Why did the HOLX board approve this? I want full-time management at the companies that I own shares.

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.